Table 3 Comparison of DOT from real-world reports and phase 3 clinical studies in RRMM patients after 1–3 prior lines of therapy; see Supplementary Table S5 for full details of studies cited for each range/piece of data
From: Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
Regimens | Phase 3 clinical studies | Real-world reports | ||
|---|---|---|---|---|
All reports identified | Studies/registry analysesa | EMR/chart review analysesb | ||
All regimens combined | Not applicable | 2.1–7 | 4.6 | 2.1–7 |
PI doublet / PI-basedc | Btz: 4–6.2 Cfz: 9.2 | Btz: 3.7–6.6 Cfz: 2.3–4.6 | Btz: 4.1–4.5 Cfz: 3.4 | Btz: 3.7–6.6 Cfz: 2.3–4.6 |
PI-alkylator triplet | NRd | 5 | NR | 5 |
Injectable PI-immunomodulatory drug triplet | 5.2–20.3 | 3.4–8.7 | 5 | 3.4–8.7 |
Oral PI-immunomodulatory drug triplet | 15.7 | 5.5–7.2 | 5.5e–7.2 | 5.5 |
Len doublet/len-basedc | 10.1–13.8 | 3.1–16.8 | 4.9–5.6 | 3.1–16.8 |
